NCT01065935

Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 87 (actual)
• Sponsor: Alnylam Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of ALN-RSV01 plus standard of care in RSV infected lung transplant patients

Conditions

• Respiratory Syncytial Virus Infections

Interventions

Type	Name	Description
DRUG	ALN-RSV01	Administered by nebulization once daily for 5 days
DRUG	Normal Saline	Administered by nebulization once daily for 5 days

Timeline

• Start date: 2010-02-01
• Primary completion: 2012-04-01
• Completion: 2012-05-01
• First posted: 2010-02-10
• Last updated: 2018-02-05

Locations

33 sites across 6 countries: United States, Australia, Austria, Canada, France, Germany